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ABSTRACT 
 
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease, yet its etiology 
as well as pathogenesis remains poorly understood. There is increasing evidence that 
aberrant expression of CD4+T lymphocytes plays an essential role in the progression of 
different pathologies such as UC. This study aimed to evaluate the circulatory frequency of 
T-helper 22 (Th22), a subset of CD4+ T cells, and serum level of its signature cytokine, IL-
22, in patients with UC. 
Blood samples from 30 patients with UC and 30 controls (n=30) were tested for IL-22 
level and circulatory Th22-cell count by ELISA and Flow cytometric analysis, respectively. 
Our results revealed higher serum level of IL-22 as well as circulatory frequency of Th22 
cells in patients with UC compared to those in healthy controls. Notably, effective factors on 
severity of the disease were age, Th22, IL-22, ESR and CRP.  
We conclude that elevated circulating Th22 cells and their signature cytokine, IL-22, may 
be implicated in the pathogenesis of UC. These findings may provide preliminary 
experimental clues for the development of new therapies for UC and its severity judgment. 
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INTRODUCTION 
 
Ulcerative colitis (UC), a chronic relapsing 
inflammatory bowel disease (IBD), is a major threat of 
public health worldwide.
1
  
It is characterized by periods of remission 
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punctuated by clinical exacerbations and frequent 
relapses in which 1% of the patients promote to 
cancer.
2
 Previous studies have revealed important  
roles of different arms of immune system
3
 such as IL-
22 cytokine in the pathogenesis of IBD
4
 and UC.
5
 IL-
22 is a unique cytokine produced by immune cells
6
  
and acts solely on non-immune tissue cells
7
 such as 
intestinal epithelium
8
 to increase their innate immunity, 
protect them from damage, and enhance their 
regeneration.
8
 From the point of immune activities on 
epithelium, IL-22 induces the production of 
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antibacterial products
5,6,9
 as well as chemokines
10
  
and enhances migratory ability of epithelial cells.
6,11
 
IL-22 may also amplify the effects of IL-1β, TNF-α, 
IL-17 and IFN-γ to some extent; thereby, it may 
enhance the pathogenic role of such cytokines.
8
 
Actually, IL-22 up-regulation has been reported in 
rheumatoid arthritis,
12
 Crohn’s disease,4 psoriasis,6 and 
atopic dermatitis,
13
 whereas its serum down-regulation 
has been demonstrated in sarcoidosis and systemic 
lupus erythematosus.
4
 Inducing antimicrobial, 
proliferative, and antiapoptotic effects, IL-22 helps 
tissue repair. All of such processes play a beneficial 
role in UC by enhancing intestinal barrier integrity and 
epithelial innate immunity.
14
 
Th22 cells, a T-cell subset with novel functional 
profile, produce cytokines such as IL-22, IL-26, and 
IL-13 of which IL-22 is the most important regulating 
inflammatory responses in some autoimmune 
diseases.
15
 Increased number of IL-22-positive cells in 
the lamina propria of UC mucosa
5
 may promise some 
potential therapeutic effects of IL-22 in such pathology, 
i.e. treatment with recombinant IL-22 or gene delivery 
of IL-22 may alleviate tissue destruction during 
inflammatory responses.
4
 From this point, Th22 cells 
provide a cellular target for therapeutic intervention 
and may resolve some unknown pathways in the 
control of inflammatory diseases.
16
 
The current knowledge available about circulating 
Th22 and its related cytokines in IBD is often 
contradictory.
17,18
 The development of other studies 
like ours using such measurements evaluating the 
prognostic accuracy of Th22 pathway is still 
preliminary. Having measured the frequency of 
circulating Th22 cells as well as serum level of IL-22 in 
a group of patients with UC, we correlated such 
quantities to clinical and pathological features of the 
disease. Such measurement may be a clue to promote 
therapeutic options as well as diagnostic markers of 
disease severity. 
 
MATERIALS AND METHODS 
 
Patients 
Based on mean difference, a sample size of 30 
patients with active UC and 30 healthy volunteers  
were enrolled. All subjects selected exclusively after 
signing the informed consent form approved by the 
local Ethical Committee (No. 92027). The study 
protocol conformed to the ethical guidelines of the 
1975 Helsinki Declaration. Patients with active UC 
were diagnosed according to routine clinical, 
endoscopic and histopathological features.  
Healthy volunteers with no history of any inflammatory 
and autoimmune diseases were recruited as healthy 
controls from local Blood Donation Organization. 
Exclusion criteria were liver, kidney, rheumatoid, 
endocrine, cardiovascular, and metabolic diseases; 
cancer and a history of using any medications as well 
as smoking. Considering the anatomical site of 
endoscopic features of edema, erythema, mucosal 
friability, bleeding, erosions, ulcerations, and loss of 
the typical vascular pattern, we endoscopically 
categorized the extent of the disease into proctitis, 
proctosigmoiditis, left-sided colitis, and extensive 
colitis.
19
 The severity of UC is defined as Truelove and 
Witts classification (Table 1). 
Specimens 
Serum levels of IL-22 were measured by a 
commercial, sandwich type ELISA kit (e-Bioscience, 
USA) according to the manufacturer’s instructions. The 
results were expressed as pg/mL. Venous blood 
samples of all subjects were collected in heparin-
containing tubes. At the same time, serum was 
collected by centrifugation at 4°C, and then stored at 
−20°C until use. 
 
Flow Cytometric Analysis 
Suspensions of 2 million cells/mL in RPMI-1640 
medium containing 10% fetal calf serum, 100 U/mL 
penicillin, 100 mg/mL streptomycin and 2 mM 
glutamine (Invitrogen, Carlsbad, CA, USA) were  
 
Table 1. Truelove and Witts classification of the severity 
of ulcerative colitis 
Mild 
<4 stools/day, without or with only small amounts of blood 
No fever 
No tachycardia 
Mild anemia 
ESR<30 mm/h 
Moderate 
Intermediate between mild and severe 
Severe 
>6 stools/day, with blood 
Fever > 37.5˚C 
Heart rate> 90/min 
Anemia with Hgb level <75% of normal 
ESR >30 mm/h 
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prepared from peripheral blood mononuclear cells 
(PBMCs) isolated on standard Ficoll-Hypaque. The 
cells were stimulated by 50 ng/mL phorbol myristate 
acetate (Sigma-Aldrich, USA) and 1 μg/mL ionomycin 
(Sigma-Aldrich) for 5 hours in the presence of 1mL 
Golgystop (BD-Bioscience, USA). After being washed 
once in phosphate-buffered saline (PBS),  
the cells were incubated in the dark at 4°C for 30 
minutes to stain the surface with the anti-human CD4-
FITC (eBioscience, USA). The cells were fixed, 
permeabilized (fixation-permeabilization buffer, 
eBioscience, USA) and incubated in the dark at 4° C  
for 30 minutes for intracellular staining with anti-
human IL-22-PE (BD-Bioscience). Stained cells were 
analyzed by flowcytometric analysis using a BD FACS 
Calibur cytometer (BD Pharmingen, UAS) equipped 
with Cell Quest software. 
 
Statistical Analysis 
Data were expressed as mean ±SD. The statistical 
indices of IL-22 levels as well as Th22 counts were 
analyzed using one-way Anova and chi-square tests. 
Simultaneous effects of various factors on severity of 
disease were analyzed by multinomial logistic 
regressions. Pseudo R-Square Cox and Snell and -
2loglikelihood was determined as a criterion of 
goodness-of-fit test, and p>0.2 was considered for 
exclusion from the model. p-values<0.1 were 
considered statistically significant in the model. All 
analyses were performed using the SPSS 16 software 
(SPSS Inc, SPSS Inc., Chicago, USA). 
 
RESULTS 
 
Values of the basic and clinical characteristics of 
the healthy individuals and patients at different 
severities are summarized in Table 2. 
 
Alteration of the Serum Level of IL-22 and 
Circulatory Number of Th22 Cells in UC Patients 
Having investigated the alteration of serum levels of 
IL-22 and circulatory number of Th22 cells in UC 
patients, we found a significant increase of both 
markers compared to healthy controls (p≤0.001) 
(Figures 1A and B). The more severe the disease, the 
more serum levels of IL-22 as well as circulatory 
number of Th22 cells. 
 
Multivariate Analysis on Severity of UC 
Using multinomial logistic regression analysis to 
investigate the effect of different factors on severity of 
UC, we found a model in which effective factors on  
 
Table 2. Distribution of basic and clinical characteristic of the ulcerative colitis patients and healthy individuals 
Parameters Healthy (n=30) Patients 
p.value 
Mild (n=16) Moderate (n=9) Sever (n=5) 
Sex  
Male 
Female 
 
10 (37.0%) 
20 (60.6%) 
 
2 (7.4%) 
3 (9.1%) 
 
5 (18.5%) 
4 (12.1%) 
 
10 (37.0%) 
6 (18.2%) 
 
0.266 
Age (years) 22±9.96 38±10.95 27.78±12.02 32.5±14.37 0.007 
Extention of diseases 
Ulcerative proctitis 
Proctosigmoiditis 
Left-sided colitis 
Total colitis 
-  
4 (80.0%) 
1 (12.5%) 
0 (0%) 
0 (0%) 
 
1 (20.0%) 
6 (75.0%) 
2 (66.7%) 
0 (0%) 
 
0 (0%) 
1 (12.5%) 
1 (33.3%) 
14 (100.0%) 
- 
ESR (mm/h) 
<20 
≥20 
 
25 (69.4%) 
5 (20.8%) 
 
1 (2.8%) 
4 (16.7%) 
 
6 (16.7%) 
3 (12.5%) 
 
4 (11.1%) 
12 (50.0%) 
<0.001 
CRP(mg/L) 
<25 
≥25 
 
30 (75.0%) 
0 (0%) 
 
3 (7.5%) 4 (10.0%) 
13 (65.0%) 5 (25.0%) 
 
 
 
 
3 (7.5%) 
2 (10.0%) 
<0.001 
Th22 0.77±0.63 1.16±0.5 1.49±0.99 1.99±1.3 0.001 
IL-22 21.9±10.6 38.6±14.02 40.6±11.9 46.6±12.57 <0.001 
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Figure 1. (A) The percentage of circulating Th22 cells in patients with active ulcerative colitis compared to healthy controls 
(B) The level of IL-22 of all subjects in the four groups 
 
 
UC severity were age, the number of circulatory Th22 
cells, the serum level of IL-22, ESR and CRP 
(dependent variables) (p<0.01). -2log likelihood from 
166.3 in null model (the model with only constant) 
reached to 41.6 in saturated model (p<0.001). It means 
that such model yields a proper goodness-of-fit in 
which Cox and Snell pseudo R Square was 0.875 
(Table 3). The negative indices of "normal ESR" and 
"normal CRP" in our model indicate that "normal 
values of ESR as well as CRP" makes the patients 
suffer from less sever forms of the disease. 
 
Sensitivity and Specificity of Circulatory Th22 
Frequency and IL-22 Serum Levels in Determining 
of UC Severity 
Using ROC curve and Area under Curve (AUC), we 
determined the sensitivity and specificity of both 
circulatory frequency of Th22 cells and serum levels of 
IL-22 as diagnostic markers of UC severity. In the best 
cutoff point of circulatory frequency of Th22 
cells=0.885, sensitivity and specificity were 83.3%  
and 53.3%, respectively; and AUC was determined as 
0.774 (Table 4).  
 
Table 3. Parameters of multinomial logistic regression model showing variables effective on ulcerative colitis severity 
Severity B Std. Error Wald df Sig. Exp (B) 
Mild age 16.373 101.307 0.026 1 0.872 1.290 
Th22 338.165 2442.430 0.019 1 0.890 7.299 
IL-22 16.134 113.073 0.020 1 0.887 1.016 
[ESR=0] -967.627 938.009 1.064 1 0.302 0.000 
[CRP=0] -610.503 6044.886 0.010 1 0.920 7.275 
Moderate age 16.222 101.306 0.026 1 0.873 1.109 
Th22 339.059 2442.430 0.019 1 0.890 1.784 
IL-22 16.103 113.073 0.020 1 0.887 9.852 
ESR (normal) -957.232 938.001 1.041 1 0.307 0.000 
CRP (normal) -613.639 6044.885 0.010 1 0.919 3.161 
Severe age 16.280 101.306 0.026 1 0.872 1.176 
Th22 339.556 2442.430 0.019 1 0.889 2.934 
IL-22 16.096 113.073 0.020 1 0.887 9.786 
[ESR=0] -959.616 937.998 1.047 1 0.306 0.000 
[CRP=0] -614.323 6044.885 0.010 1 0.919 1.595 
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Table 4. Sensitivity and specificity of Th22 number cells and IL-22 levels in determining of ulcerative colitis severity 
AUC NPV PPV Specificity Sensitivity Cutoff point Inflammatory 
markers 
0.774 73.7% 61% 53.3% 83.3% 0.885 Th22 
0.868 83.3% 72.2% 66.7% 86.7% 27.1 IL22 
 
 
DISCUSSION 
 
Recent findings have revealed that the imbalance of 
T lymphocytes plays an important role in the 
pathogenesis of UC.
20
 Regarding Th22 subset of 
CD4+T cells, such imbalance has been demonstrated in 
several autoimmune diseases such as rheumatoid 
arthritis
21
 and immune thrombocytopenic purpura.
22
 
Th22 cells produce IL-22 which is expressed also by 
Th17 and NK cells.
23
 The foremost protective role of 
such cell populations via IL-22 production has been 
demonstrated in various chronic inflammatory 
diseases.
8
 IL-22 mediates some crosstalk between 
immune and non-immune cells especially epithelial 
cells.
24
 At such basis, the massive presence of IL-22 
has been reported in affected tissues of inflammatory 
diseases such as autoimmune hepatitis and cholestatic 
liver disease,
8
 psoriasis,
6
 atopic dermatitis,
7
 IBD,
25
 
rheumatoid arthritis,
21
 cystic fibrosis,
26
 and multiple 
sclerosis.
27
 Moreover, elevated IL-22 expression has 
been observed in human infectious diseases such as 
Mycobacterium tuberculosis infection in which IL-22 
levels are increased in the bronchoalveolar lavage 
fluid.
28
 
A preventive role of IL-22 has been proposed in 
Crohn’s disease.29 In line with such concept, IL-22 
gene delivery led to rapid amelioration of local 
intestinal inflammation through both  STAT3-
dependent expression of mucus-associated molecules 
and restitution of mucus-producing goblet cells in a 
mouse model of UC.
30
 Moreover, a regulatory role of 
IL-22 in IBD has recently been proposed due to the 
ability of IL-22 to dampen systemic inflammatory 
response through the induction of lipopolysaccharide-
binding protein.
25
 In contrast, IL-22 antagonism might 
be a promising therapy for alleviation of inflammatory 
responses of the psoriasis.
31
 Thus, the role of IL-22 in 
different epithelial cells like IBD may be still unclear 
and remains to be established. 
In the present study, our results revealed that levels 
of circulating Th22 cell and IL-22 serum levels were 
significantly increased in patients with UC. Our model 
also revealed that factors like age, the frequency of 
Th22 cells, serum levels of IL-22, ESR and CRP may 
have a positive correlation with severity of the disease. 
Therefore, we hypothesized that aberrant expression of 
Th22 pathway may play an important role in the 
pathogenesis of UC. It may be considered that the 
elevation of IL-22 serum levels as well as Th22 
circulatory frequencies in our study could be one 
probable compensatory protective mechanism of tissue 
injury in UC. These findings may help to broaden our 
knowledge concerning the immunopathological role of 
these cells in the progression of UC. 
The limitation of our study was lack of monitoring 
serum levels of IL-22 as well as circulatory frequencies 
of Th22 cells longitudinally. This limitation allowed 
just a cross-sectional analysis of such changes of only 
limited robustness. Secondly, functional assays which 
provide further information on the possible 
immunoregulatory mechanism of Th22 pathway were 
not performed. 
We conclude that elevated circulating Th22 cells 
and their signature cytokine, IL-22, may be implicated 
in the pathogenesis of UC. Such implication may be 
related to disease alleviation. Therefore, these findings, 
provided that be confirmed by more studies with larger 
sample size, may provide preliminary experimental 
clues for the development of new therapies for UC and 
its severity judgment. 
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